When a specialty pharma company completes its major Phase 3 programs, R&D expenses decline structurally even while the commercial ramp is accelerating. Because SG&A growth (commercial build-out) is typically smaller than the R&D reduction (clinical programs are expensive — $100-200M+/year), total opex can be flat or declining while revenue doubles. The result is near-unity incremental operating margins: approximately $1 of operating income per $1 of incremental revenue.
Before analyzing a specialty pharma's cost trajectory, identify whether major Phase 3 programs are recently completed or within 1-2 quarters of completion. Phase 3 program completion is a structural R&D cost reduction catalyst that is easy to miss when looking at trailing financials. This predicts a step-function improvement in incremental operating margins regardless of revenue trajectory. The diagnostic: check the pipeline section of the 10-K for program completion dates and cross-reference against the R&D expense trajectory. A 5-15% R&D reduction from Phase 3 completion, when combined with commercial-stage revenue scaling, can produce opex-flat quarters during 80-110% revenue growth — creating the optical illusion that margins are already at steady-state when the business is actually still in high-investment mode.